
Objective: Immune checkpoint inhibitor (ICI) therapies, such as anti-PD-1 treatment, have achieved great success in various cancers, including hepatocellular carcinoma. Tumor-infiltrating lymphocytes have major roles in the mechanism of action for ICIs, but numerous other components of the tumor microenvironment also contribute to the effectiveness of immunotherapy. However, little is known about the changes in the tumor microenvironment after ICI therapy, which may sustainably affect tumor progression. Methods: Integrated single-cell RNA sequencing data were collected for hepatocellular carcinoma (HCC) patient samples and analyzed to characterize immune cell alterations within the tumor microenvironment. Three different orthotopic allograft HCC models were established for ICI therapy and microenvironment component detection by using flow cytometry and multiple ELISA assays. Transwell assays were combined with flow cytometry to evaluate neutrophil migration. In vitro coculture systems were employed to investigate communication between different cell types. Multiplex immunochemistry analysis was conducted for human clinical samples to confirm the findings. Results: Our results indicate that neutrophil infiltration was significantly reduced after effective ICI therapy, but not in patients with failed immunotherapy. Mechanistically, we found that effective anti-PD-1 therapy activates T cells, which secrete interferon-γ and other cytokines that act on tumor-associated macrophages. This T cell–macrophage crosstalk suppresses tumor-associated neutrophil-related chemokines secreted by macrophages. Consequently, neutrophil infiltration into the tumor microenvironment is diminished. Conclusion: Our findings show that immunotherapy reinvigorates T cells, but also remodels the myeloid compartment and reduces neutrophil recruitment, potentially alleviating neutrophil-mediated immunosuppression, thereby providing potential myeloid-targeted combinatorial strategies for improving checkpoint blockade responses.
Objective: Spinal cord gliomas with wildtype histone H3 (H3WT-SCGs) are rare but heterogeneous tumors for which pathological classification is challenging. Our aim was to characterize a methylation-based molecular classification of H3WT-SCGs. Methods: We characterized H3WT-SCGs from 55 patients using data from DNA methylation arrays, whole-exome/transcriptome sequencing, proteomics, phosphoproteomics, single-cell RNA sequencing, and multiplex staining. Another 31 cases with DNA methylation data were used for validation. Results: Using DNA methylation data, we identified six spinal cord methylation (SCM) subtypes: pilocytic astrocytoma (PA), PA-immune enriched (PA-IME), diffuse leptomeningeal glioneuronal tumor (DLGNT), subependymoma (SUBEPN), glioblastoma-like (GBM), and pleomorphic xanthoastrocytoma-like (PXA). These SCM subtypes exhibited a distinction from the traditional histology classification in 58.2% of the study cases. In comparison to histology, SCM subtyping better correlates with independent molecular features, as evidenced by significant enrichment of BRAF fusions in the PA and DLGNT classes, and notable enrichment of chromosome 1p losses and 1q gains in DLGNT. SCM-PA can be further divided into pediatric (SCM-PA-P) and adult (SCM-PA-A) subgroups. In comparison to SCM-PA-P, SCM-PA-A was associated with lower BRAF fusion frequency (P < 0.01), smaller tumor size (P < 0.01), and longer progression-free survival (P = 0.036; all patients alive). Neoplastic cells in SCM-PA-A exhibited a less differentiated status with higher expression of neuronal markers and lower expression of cytokines and chemokines in comparison to SCM-PA-P. In addition, SCM-PA-A had a lower senescence-associated secretory phenotype, lower infiltration of immunosuppressive monocyte-derived macrophages, and less proliferative myeloid cells in comparison to SCM-PA-P. Conclusions: This study defined clinically relevant H3WT-SCG molecular classes that reflect patient prognosis and molecular characteristics for potential therapeutic strategies.
Objective: To develop a pathology-based preoperative decision-support system (Structured Imaging Report System for Pancreatic Cystic Lesions, SIRS-PCL) for subtype classification and risk stratification of PCLs. Methods: We conducted a multicentre retrospective study involving 1,102 patients treated between 1 January 2011 and 31 December 2024. The study cohort was divided into a development dataset ( n = 858) and a temporal validation dataset ( n = 244) from the periods 2011–2022 and 2023–2024, respectively. Three logistic prediction models were used to classify the five PCL subtypes and to perform separate three-tier risk stratifications (benign/low, medium, and high) for intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) cases. SIRS-PCL was prospectively implemented at Tianjin Medical University Cancer Institute and Hospital from 25 June 2025 to 25 June 2026, and the diagnostic accuracy, sensitivity, and specificity were evaluated in a cohort of 76 patients. Results: A total of 1,102 patients with PCLs were included in the study (median age 56 years, interquartile range 44–64), of whom 714 were female (64.8%). The five-category model included in SIRS-PCL achieved a mean area under the receiver operating characteristic curve (AUC) of 0.93 [95% confidence interval (CI) 0.91–0.95] in temporal validation. The IPMN model showed good discrimination for risk stratification (mean AUC 0.86, 95% CI 0.79–0.93), with the highest overall accuracy of 77.1% exceeding current guidelines (range 50.0%–58.6%). The MCN risk model also showed high performance (mean AUC 0.97, 95% CI 0.91–1.00). In comparison to current practice, SIRS-PCL use reduced unnecessary surgeries 11.5% vs . 23.1% and over-examinations 6.7% vs 33.7%. In the prospective implementation cohort, SIRS-PCL achieved accuracy of 86.2% for five-category pathological classification, 73.7% for IPMN risk stratification, and 100% for MCN risk stratification. Conclusions: SIRS-PCL is a pathology-based, quantitative decision-support system for preoperative pathological subtype classification and pathological risk stratification of surgically evaluated neoplastic PCLs.
Objective: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended for patients receiving chemotherapy with a high risk of febrile neutropenia (FN), but its use remains suboptimal in patients receiving intermediate-risk regimens who have additional risk factors, for whom secondary prophylaxis (SPx) is commonly used despite limited prospective evidence comparing the two approaches. This study evaluated efbemalenograstim alfa (EFBG alpha), a novel Fc fusion G-CSF, as primary or secondary prophylaxis for chemotherapy-induced neutropenia (CIN) in patients with non-small-cell lung cancer (NSCLC) receiving intermediate-risk FN regimens who have additional risk factors. Methods: This multicenter, randomized phase II trial enrolled chemotherapy-naive patients with stage IIIB/IV NSCLC scheduled for platinum-taxane chemotherapy. Patients were randomized 2:1 to either primary prophylaxis (EFBG alpha 20 mg at 48 +/- 4 h after each cycle) or secondary prophylaxis (given only after grade 3-4 neutropenia). The primary endpoint was the cycle 1 incidence of grade 3-4 neutropenia. Results: A total of 102 patients were enrolled between February 2024 and December 2025, of whom 96 were included in the analysis: 63 in the primary prophylaxis group and 33 in the secondary prophylaxis group. In cycle 1, the incidence of grade 3-4 neutropenia was lower with primary prophylaxis than with secondary prophylaxis [20.6%, 95% confidence interval (CI) 11.5%-32.7% vs. 57.6%, 95% CI 39.2%-74.5%; risk difference -36.9%, 95% CI -52.4% to -16.1%; P < 0.001]. The median duration of grade 3-4 neutropenia was comparable between the groups (P = 0.144). Cycle 1 FN incidence was 1.6% in the primary and 6.1% in the secondary prophylaxis group. Treatment-related adverse events were mostly grade 1-2, with pain-related events (7.0%) being the most common. Conclusions: EFBG alpha exhibited promising efficacy and tolerability for CIN prophylaxis in patients with NSCLC and additional risk factors who are receiving intermediate-risk chemotherapy (IRC). The results support its use in both primary and secondary prophylactic strategies, and earlier initiation was associated with better CIN control.
Objective: Transcriptomic perturbation profiles from tumor cell lines serve as the core molecular basis for cancer drug discovery and mechanism of action (MOA) analysis. Traditional Chinese medicine (TCM) holds great anticancer potential, yet the multi-component and multi-target properties pose major challenges for systematic mechanistic investigation. The scarcity of herbal intervention transcriptomic data severely restricts transcriptome-based anticancer TCM research, unlike widely available large-scale chemical compound perturbational datasets. This study aims to establish a predictive framework for herbal transcriptional responses in tumor cell models to address this critical data bottleneck. Methods: A transfer learning-based encoder-decoder prediction framework integrated with a self-attention mechanism was developed. The model was pre-trained on large-scale connectivity map compound perturbation datasets with paired baseline transcriptomic profiles, then fine-tuned with limited herbal perturbation data covering 11 herbs across 4 tumor cell lines using a shared gene set as the molecular basis. Results: The model achieved strong predictive performance (mean squared error = 0.1395, R2 = 0.8561, Pearson correlation coefficient = 0.9258), outperforming baseline models with robust generalization to unseen herbal interventions. Transfer learning markedly improved prediction accuracy and stability under data-limited conditions. Conclusions: This framework provides a scalable, cost-effective computational approach for anticancer herbal in silico screening, preliminary MOA exploration, and multi-herb prescription synergistic pattern analysis in cancer drug discovery.